Merck has a strong vaccine and drug portfolio, led by cancer drug Keytruda

The combination of Merck’s broad portfolio of high-margin drugs and its pipeline of new drugs should provide high returns on invested capital over the long term. In addition, following the sale of the Organon business in June 2021, Merck’s remaining portfolio includes a higher percentage of drugs with strong patent protection. In the pipeline, after several years of only moderate R&D productivity, Merck’s drug development strategy is delivering important new drugs.